Advisor Group’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Advisor Group’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$0	Hold	14	–	–	﹤0.01%	5575
2019 Q3	$0	Hold	14	–	–	﹤0.01%	5543
2019 Q2	$0	Hold	14	–	–	﹤0.01%	5486
2019 Q1	$0	Sell	14 -40	-74%	-$217	﹤0.01%	5419
2018 Q4	$0	Hold	54	–	–	﹤0.01%	5350
2018 Q3	$1K	Buy	54 +14	+35%	+$354	﹤0.01%	5049
2018 Q2	$1K	Hold	40	–	–	﹤0.01%	4874
2018 Q1	$1K	Hold	40	–	–	﹤0.01%	4897
2017 Q4	$3K	Buy	+40	New	+$2.96K	﹤0.01%	4632

Other funds holding MLNT

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

CCM

Condor Capital Management Martinsville, New Jersey $1.33B AUM 19.79% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $203M AUM 34.78% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Advisor Group's MLNT Position: Q4 2019 in Review

Advisor Group held its Melinta Therapeutics, Inc. Common Stock (MLNT) position steady in Q4 2019 at 14 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5575.

Advisor Group first reported a position in MLNT in Q4 2017 and has held it in 9 quarters since. The position peaked at $3K in Q4 2017. 37 funds tracked by Wall St. Rank hold MLNT as of Q4 2019.

Advisor Group held 14 shares of Melinta Therapeutics, Inc. Common Stock worth $0 as of Q4 2019.
Advisor Group left its Melinta Therapeutics, Inc. Common Stock share count unchanged in Q4 2019.
Melinta Therapeutics, Inc. Common Stock made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #5575 holding.
Advisor Group first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and has held it in 9 quarters since.
Advisor Group's Melinta Therapeutics, Inc. Common Stock position peaked at $3K in Q4 2017.
37 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.